Sana Biotechnology SANA, a gene-editing company, creates and delivers engineered cells as medicines for patients. The company recently secured three investigational new drug (IND) application ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Advancing a single biologic drug candidate to clinical trials on a fast-track timeline is a tall order for many biotech startups. Sana Biotechnology has quietly built a pipeline of 11 preclinical cell ...
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Sana Biotechnology (SANA) is another one of those high-valued cell therapy companies with no trial data available so far. Yet it has a market cap of $1.4bn. So let’s explore what it is all about.Sana ...
Sana Biotechnology Inc. has received FDA clearance of its IND application to initiate a first-in-human study of SC-291 in patients with various B-cell malignancies. Initial clinical data from the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results